Systematic review of clinical guidance for lipid management in adults with or at risk of atherosclerotic cardiovascular disease: A global perspective Authors: Katherine G Akers, Kara Nguyen, Andrew M Frederickson, Lori D Bash, Xuehua Ke, Shaun G Goodman Published: 2026 ABSTRACT AbstractAimsTo identify clinical guidance globally on lipid management in adults who are at risk of or diagnosed with atherosclerotic cardiovascular disease (ASCVD) and to summarize recommendations for patients with increasingly prevalent diseases (i.e., diabetes, chronic kidney disease, and obesity), older adults, and women.MethodsA systematic review of clinical guidance published within the last 10 years was performed by searching Embase, MEDLINE, and guideline-specific databases. Relevant guidance documents were selected by two independent reviewers. Recommendations pertaining to lipid testing, low-density lipoprotein cholesterol (LDL-C) goals, lifestyle modifications, and lipid-lowering treatment were extracted.ResultsA total of 109 clinical practice guidelines and expert consensus statements were identified, which were international (10%) or developed within Europe or the United Kingdom (31%), Asia-Pacific (26%), the United States or Canada (23%), Latin America (5%), the Middle East (5%), or Africa (<1%). Although clinical guidance provides common recommendations for lipid management in patients at risk of or diagnosed with ASCVD, including patients with diabetes or chronic kidney disease, recommendations concerning LDL-C goals and use of non-statin therapies often differ across guidance documents. Furthermore, recommendations specific to older adults, women, and patients with obesity are sparse.ConclusionsAlthough clinical guidance from around the world provides a common framework for lipid management, important differences remain in recommendations concerning LDL-C goals, use of non-statin therapies, and management of certain patient populations. Future research and guidance development may help address these gaps and improve the consistency and applicability of recommendations across healthcare settings.Keywords: Clinical practice guidelines, Expert consensus, Lipid management, Lipid-lowering therapy, Low-density lipoprotein cholesterol, Atherosclerotic cardiovascular disease Introduction Low-density lipoprotein cholesterol (LDL-C) in the blood contributes to the buildup of plaque in artery walls. This plaque buildup can disrupt blood flow and cause atherosclerotic cardiovascular disease (ASCVD), which can lead to acute cardiovascular (CV) events (e.g., myocardial infarction, ischemic stroke) and is the leading cause of morbidity and mortality worldwide [[1], [2], [3]]. For prevention of a first CV event, people with risk factors but who have not yet developed ASCVD are advised to adopt a healthy lifestyle and may receive lipid-lowering treatment (LLT) to reduce LDL-C with the goal of preventing ASCVD. Among those with existing ASCVD, prevention steps may include more aggressive LLT to further reduce LDL-C and the risk of recurrent CV events. These LLTs include statins and non-statin medications such as ezetimibe, bile acid sequestrants, bempedoic acid, and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in the form of monoclonal antibodies and small interfering RNA [4,5]. Clinicians involved in managing patients’ lipid levels often rely on clinical practice guidelines or expert consensus statements (both henceforth referred to as “clinical guidance”) to support their decision-making. Usually developed by a panel of experts from professional associations or a particular area of practice, clinical guidance aims to improve the quality, consistency, and efficacy of patient care by providing clear recommendations on how patients should be tested, treated, and/or monitored based on the highest-quality evidence available [[6], [7], [8]]. Depending on how this evidence is selected and evaluated and how expert consensus is achieved, however, recommendations may differ across guidance documents. For example, a study comparing three major clinical practice guidelines on lipid management from the United States (US), Canada, and Europe concludes that despite consistency in their main principles of treatment, specific recommendations for treatment varied somewhat due to different interpretations of the evidence [9]. Variations in guidance can also arise by country or region due to financial or resource constraints on the development and implementation of recommendations [10]. Given the high global prevalence of ASCVD and the breadth of patient subgroups at risk of ASCVD, recommendations for lipid management appear in many clinical guidance documents spanning different medical specialties and geographies [11,12]. However, this abundance of guidance can lead to uncertainty when guidance documents provide differing recommendations for patient management [[13], [14], [15]]. Thus, to facilitate the implementation of guidance on lipid management, there is a need to summarize and compare recent recommendations concerning LDL-C goals and pharmacological LLT, particularly for patients with diseases that are increasingly co-prevalent (e.g., diabetes mellitus (DM) [16], chronic kidney disease (CKD) [17], obesity [18]) or with demographic characteristics that are underrepresented in clinical research or guidance (e.g., older adults [19], women [20]). The objective of this systematic review was to identify and summarize clinical guidance globally on lipid management in adults who are at risk of or diagnosed with ASCVD. Methods The systematic review methodology and reporting followed a pre-specified review protocol and were guided by recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [21] and Cochrane handbook [22]. This review was not registered in the PROSPERO registry because it does not accept reviews of clinical practice guidelines [23]. Search strategy Relevant clinical guidance documents were identified by searching Embase and MEDLINE databases through the Ovid portal as well as ECRI Guidelines Trust, International Guidelines Library, and National Institute for Health and Care Excellence guidance databases on March 24, 2025 using predefined search strategies (Supplemental Table 1–3). The search strategies employed keywords and subject headings related to “lipid”, “low-density lipoprotein”, “LDL”, “cholesterol”, “dyslipidemia”, “hyperlipidemia”, and “hypercholesterolemia” combined with the “Guidelines – Standard” search filter from Canada's Drug Agency (modified to omit chemotherapy-specific keywords) [24], which has high sensitivity and specificity in retrieving clinical guidance [25]. Non-contributory publication types (e.g., case reports, clinical trials, conference abstracts, observational studies) were filtered out using database-specific publication types and the Scottish Intercollegiate Guidelines Network's search filter for observational studies [26]. Clinical guidance selection Criteria for inclusion The clinical guidance eligibility criteria were defined in terms of population, interventions, comparators, outcomes, time, and study design (PICOTS) (Supplemental Table 4). The population of interest was adults (≥18 years) who are at risk of or diagnosed with ASCVD, including subgroups of different sexes, age groups, risk groups, and comorbidity groups (e.g., DM, CKD, obesity). The study design of interest was clinical guidance, defined as a clinical practice guideline or expert consensus statement that (1) provides recommendations for the population of interest, (2) contains an explicit description of its methodology (e.g., search strategy, evidence grading, process of achieving consensus) within the guidance or supporting documents, (3) contains a reference list, and (4) is produced by a group of authors or an organization (i.e., not a single author) at a national, multinational, or societal level [25]. The outcomes of interest used for selecting relevant guidance were recommendations pertaining to LDL-C testing or goals and the use of pharmacological LLTs for lowering LDL-C. To capture guidance describing current clinical practice, only guidance published from 2014 to March 24, 2025 was eligible for inclusion. No intervention, comparator, or geography selection criteria were employed. Only English-language guidance documents were eligible for inclusion. Screening Two independent reviewers screened all titles/abstracts identified in the search and full texts that passed title/abstract screening. Conflicts between reviewers were resolved by reaching consensus and/or involving a third reviewer. After screening, included reports were mapped to their originating association(s) or authors to identify unique clinical guidance documents that may have been updated and published in successive years as new evidence became available, published simultaneously in more than one journal, or published as separate full-length and summary publications. Data extraction One reviewer extracted data from the most recently published or authoritative version of each unique clinical guidance document, and a second reviewer validated the extracted data against the original publication. Conflicts between reviewers were resolved by reaching consensus and/or involving a third reviewer. Data were extracted on general guidance characteristics and specific recommendations pertaining to ASCVD risk assessment, LLT goals, pharmacological LLT, monitoring and follow-up, and care coordination for each relevant patient subgroup. Quality assessment The methodological quality of the most recently published or authoritative version of each unique clinical guidance document was assessed using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument [27]. This instrument is used to assess the quality of guidance in six domains—scope and purpose, stakeholder involvement, rigor of development, clarity of presentation, applicability, and editorial independence—in terms of a quality score reflecting the percentage of the maximum possible score (i.e., 0 to 100) for each domain. In addition, reviewers provided two subjective overall assessments of each guidance document: (1) its overall quality on a Likert scale from 1 (lowest possible quality) to 7 (highest possible quality) and (2) whether the reviewer would recommend its use (“yes”; “yes, with modifications”; or “no”). One reviewer performed the assessment, and a second reviewer validated the assessment against the original publications. Conflicts between reviewers were resolved by reaching consensus and/or involving a third reviewer. Summary of recommendations Recommendations for lipid testing, LDL-C goals, lifestyle modifications, and pharmacological LLT were qualitatively summarized across clinical guidance documents for general populations of patients at risk of or diagnosed with ASCVD, specific subgroups of patients with increasingly prevalent comorbidities (i.e., DM, CKD, obesity), and specific subgroups of patients with demographic characteristics that may be underrepresented in clinical research or guidance (i.e., older adults, women). Results Guidance selection The literature search yielded 4089 reports, of which 185 passed both title/abstract and full-text screening (Fig. 1). After mapping the included 185 reports to their originating association(s) or authors, a total of 109 unique clinical guidance documents providing recommendations on lipid management for patients at risk of or diagnosed with ASCVD were identified (Supplemental Table 5). PRISMA flow diagram depicting guidance selection process. General guidance characteristics Of the 109 clinical guidance documents identified, 31% are from professional associations or author groups spanning Europe, within individual European countries (i.e., Belgium, France, Greece, Poland, Portugal, Spain), or within the United Kingdom (UK); 26% are from the Asia-Pacific region or individual Asian-Pacific countries (i.e., Australia/New Zealand, China, Hong Kong, India, Japan, Malaysia, the Philippines, South Korea, Taiwan, Thailand); 23% are from the US or Canada; 10% are international (i.e., spanning multiple continents or world regions); 5% are from the Latin America region or individual Latin American countries (i.e., Brazil, Mexico), 5% are from the Middle Eastern region or individual Middle Eastern Countries (i.e., Iran, Jordan, Saudi Arabia), and <1% are from Africa (i.e., South Africa). More clinical practice guidelines (63%) than expert consensus statements (37%) were identified, with most of both types of guidance relying on clinical research evidence to support their recommendations (98% of clinical practice guidelines and 85% of expert consensus statements). The largest proportion of clinical guidance documents (36%) broadly cover multiple patient groups at risk of or diagnosed with ASCVD, including groups defined by demographic (e.g., age, sex), comorbidity (e.g., DM, CKD, familial hypercholesterolemia [FH]), and/or CV risk factor characteristics. Other guidance documents focus exclusively on narrower patient populations: patients who are diagnosed with ASCVD (e.g., coronary artery disease [CAD], peripheral artery disease) or have experienced a CV event (e.g., stroke or transient ischemic attack, acute coronary syndrome [ACS]) (26%), patients with DM (11%), patients at risk of ASCVD (6%), patients with familial hypercholesterolemia (6%), patients with kidney or liver diseases (5%), patients with hypertension (4%), or patients with other diseases or conditions (e.g., chronic inflammatory conditions, non-diabetic endocrine disorders, overweight/obesity, erectile dysfunction) (7%). The distribution of guidance by overall patient population and geographical region is shown in Fig. 2. Sunburst plot showing distribution of clinical guidance documents (n = 109) by patient population and region. ASCVD, atherosclerotic cardiovascular disease; DM, diabetes mellitus; FH, familial hypercholesterolemia; HTN, hypertension; ROW, rest of the world; UK, United Kingdom; US, United States. The methodological quality of clinical guidance was assessed using the AGREE II instrument [27]. Altogether, the guidance documents scored highest in the scope and purpose domain (median [interquartile range]: 100 [17]), followed by stakeholder involvement (89 [17]), clarity of presentation (89 [22]), and rigor of development (85 [21]) domains. The lowest scores were observed for applicability (75 [21]) and editorial independence (50 [0]). Overall, 18% of guidance documents received the highest possible overall quality score of 7, 43% received a score of 6, 32% received a score of 5, and 7% received a score of 4 (Supplemental Table 6). Lipid management recommendations General population At risk of ASCVD Lipid testing. Clinical guidance typically recommends that individuals at risk of ASCVD undergo a lipid profile (typically consisting of LDL-C, high-density lipoprotein cholesterol, total cholesterol, and triglycerides), with the frequency of testing ranging from once every 5 years to annually depending on the specific guidance and patient characteristics [[28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59]]. LDL-C goals. The recommended LDL-C goal for individuals generally considered to have moderate/intermediate CV risk (e.g., ≤2 risk factors in individuals without DM, no major risk factors in patients with DM lasting <10 years) is typically <100 mg/dL [[28], [29], [30],32,33,36,39,40,42,46,47,52,60] (or ≥30% reduction from baseline without mention of specific target levels [37,61]). However, guidance documents from several Asian-Pacific countries [35,54,59,[62], [63], [64]] and South Africa [43] recommend less aggressive goals ranging from <140 to <115 mg/dL, and French [34] and Canadian [41] guidance documents do not recommend specific target levels but instead recommend initiating LLT if LDL-C ≥130 mg/dL. The recommended LDL-C goal for individuals generally considered to have high CV risk (e.g., markedly elevated total cholesterol, LDL-C, and/or blood pressure; ≥2 risk factors in individuals without DM; DM without target organ damage, lasting ≥10 years, or with another risk factor; moderate CKD; or FH without major risk factors) is < 100 mg/dL [34,35,38,40,42,43,45,54,55,59,62,65] or <70 mg/dL [[28], [29], [30],32,33,36,47,49,[51], [52], [53],58,60,66], with the less aggressive goal recommended by most Asian-Pacific guidance documents and the more aggressive goal recommended by most European guidance documents. However, Japanese guidance recommends an even less aggressive goal of <120 mg/dL [64]. Also, some US guidance documents recommend a ≥50% reduction in LDL-C without mention of specific target levels [37,61], and some international [67], US [57], and Canadian [44] guidance documents do not recommend LDL-C goals but instead recommend specific treatments based directly on their beneficial effects on CV outcomes. The recommended LDL-C goal for individuals generally considered to have very high CV risk (e.g., DM lasting >20 years with target organ damage or other major risk factors, severe CKD, or FH with another major risk factor) is either <70 mg/dL [30,40,42,59,62,68] or <50-55 mg/dL [28,29,32,36,47,[51], [52], [53],58,60,66], with the more aggressive goal recommended by most European guidance documents. Lifestyle modifications. Most clinical guidance documents recommend that individuals at risk of ASCVD adopt a healthy diet, regularly engage in physical activity, manage their weight, and cease smoking [28,[30], [31], [32], [33], [34], [35], [36], [37],[39], [40], [41], [42], [43], [44], [45], [46], [47],51,[53], [54], [55], [56], [57], [58], [59],[61], [62], [63], [64], [65],67,69]. Lipid-lowering treatment. Statin alone is typically recommended as initial pharmacological LLT for individuals at risk of ASCVD [28,[30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47],49,[51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65],[67], [68], [69], [70], [71]], although statin + ezetimibe is recommended as another initial option by French guidance for individuals with any CV risk [36], Polish guidance for individuals with very or extremely high CV risk [32], and international [51] and Indian [52] guidance if marked reductions in LDL-C are needed. However, some Canadian [44] and US [45] guidance documents recommend not initiating statins in individuals with a relatively low CV risk and instead retesting lipid levels in 5-10 years or emphasizing lifestyle modifications, respectively. For individuals not meeting initial LLT goals, most guidance documents recommend adding ezetimibe [28,35,39,43,53,60,62,67], ezetimibe or a bile acid sequestrant [31,37,41,47,54,55,58], ezetimibe or PCSK9i [33,42,51,65], or any of these three agents [59]. Several guidance documents recommend adding ezetimibe, bempedoic acid, and/or a bile acid sequestrant for lower-risk individuals, with the addition of PCSK9i reserved for higher-risk individuals [30,32,36,40,45,52,56]. For individuals not meeting second-line LLT goals and requiring third-line LLT, most guidance documents recommend the three-agent combination of statin + ezetimibe + PCSK9i [28,32,35,37,39,40,43,47,51,56,58,60,72]. However, some guidance documents also recommend the addition of a bile acid sequestrant or bempedoic acid [2,32,73]. Non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants are recommended for individuals with statin intolerance [28,[30], [31], [32],[34], [35], [36], [37],39,40,42,43,[45], [46], [47],51,[53], [54], [55], [56],58,59,63,65,67,70]. Diagnosed with ASCVD Lipid testing. Clinical guidance typically recommends that patients who are diagnosed with ASCVD or have experienced a severe ASCVD event undergo a lipid profile, with testing occurring as soon as possible in patients with ACS [30,43,48,59,[74], [75], [76], [77], [78], [79], [80]]. LDL-C goals. The recommended LDL-C goal for patients diagnosed with ASCVD (with or without other major risk factors) or have experienced one severe ASCVD event is either <70 mg/dL [33,34,38,40,42,43,48,49,54,59,62,65,68,74,[81], [82], [83], [84], [85], [86], [87], [88], [89], [90]] or <50-55 mg/dL [[28], [29], [30],32,42,46,47,51,52,58,60,63,66,70,78,80,83,[91], [92], [93], [94], [95], [96]], with the more aggressive goal recommended by most European guidance. Some Asian-Pacific guidance documents recommend goals of either <70 or <55 mg/dL depending on patients' ASCVD history and CV risk classification [46,97]. However, some Japanese guidance documents recommend less aggressive goals of <100 or <70 mg/dL depending on patients’ ASCVD history and CV risk classification [64,76], and South American guidance recommends even less aggressive goals of <160, <130, and <100 mg/dL for CV rehabilitation patients with 0-1 risk factors, ≥2 risk factors, and CAD risk or equivalent, respectively [76]. Furthermore, some Canadian guidance documents do not recommend an LDL-C goal but instead recommend initiating LLT if LDL-C ≥70 mg/dL [41], some US guidance documents recommend a ≥50% reduction in LDL-C without mention of specific target levels [37,98], and some international [67], US [57], and Canadian [44] guidance documents do not recommend LDL-C goals but instead recommend specific treatments based directly on their beneficial effects on CV outcomes. Clinical guidance typically recommends an LDL-C goal of <40 mg/dL for patients with two severe ASCVD events or one severe event with ≥2 major risk factors [28,29,32,47,51,80,92]. However, some US [45] and several Asian-Pacific [53,65,83,90] guidance documents recommend a less aggressive goal of <50-55 mg/dL, and Indian guidance recommends more aggressive goals of <30 mg/dL for ASCVD patients with ≥1 major CV risk factor, recurrent ACS, polyvascular disease, or homozygous FH and 10-15 mg/dL for patients with a recurrent ASCVD event despite maintaining an LDL-C around 30 mg/dL [52]. Lifestyle modifications. Most clinical guidance documents recommend that patients who are diagnosed with ASCVD or have experienced a severe ASCVD event adopt a healthy diet, regularly engage in physical activity, manage their weight, cease smoking, and moderate their alcohol consumption [[28], [29], [30], [31], [32],34,37,[40], [41], [42], [43],[45], [46], [47], [48],50,51,53,54,[56], [57], [58], [59],[63], [64], [65], [66], [67],69,[74], [75], [76],80,[83], [84], [85],87,90,[94], [95], [96],98]. Lipid-lowering treatment. Statin alone or statin + ezetimibe is typically recommended as initial pharmacological LLT for patients who are diagnosed with ASCVD or have experienced a severe ASCVD event [28,30,31,34,37,[40], [41], [42], [43],[45], [46], [47], [48], [49], [50], [51], [52], [53], [54],[56], [57], [58], [59], [60],63,64,66,67,69,70,72,74,75,[77], [78], [79], [80], [81], [82], [83],[85], [86], [87], [88], [89], [90], [91],[93], [94], [95], [96], [97], [98]]. However, several guidance documents recommend including a PCSK9i in the initial LLT regimen, particularly when patients have extremely high CV risk and/or are in need of marked reductions in LDL-C [29,44,52,65,92,93]. Also, Japanese guidance states that eicosapentaenoic acid (EPA)/icosapent ethyl can be considered alongside a statin [84,99] or that any LLT can be used depending on LLT goals [64], Indian guidance recommends bempedoic acid or a bile acid sequestrant in addition to statin + ezetimibe [52], and South American guidance indicates that ezetimibe, a bile acid sequestrant, fibrate, or niacin may be used alongside a statin in a CV rehabilitation setting [76]. For patients not meeting initial LLT goals, most guidance documents recommend adding ezetimibe [28,34,37,[46], [47], [48],53,60,63,70,72,78,80,81,90,93,95], PCSK9i [49,56], ezetimibe or PCSK9i [29,40,42,44,45,51,57,65,74,98], or ezetimibe or a bile acid sequestrant [31,47,54,58,94]. However, many guidance documents further recommend a combination of three (e.g., statin + ezetimibe + PCSK9i, bempedoic acid, or bile acid sequestrant) [30,32,43,45,47,48,52,66,67,73,84,85,88,91,92,97] or four (e.g., statin + ezetimibe + PCSK9i + bempedoic acid) [92] agents, particularly when patients are extremely high-risk and/or are in need of marked reductions in LDL-C. Also, some guidance documents recommend the addition of niacin or EPA [44,76,83]. For patients not meeting second-line LLT goals and requiring third-line LLT, most guidance documents recommend the three-agent combination of statin + ezetimibe + PCSK9i [28,31,37,43,[46], [47], [48],51,54,56,58,60,66,70,72,73,78,90,91,[93], [94], [95],100], with some guidance documents also or instead recommending statin + ezetimibe + bile acid sequestrant or bempedoic acid, such as in cases where PCSK9i is unable to be used [46,48,53,73,80,100]. Also, international guidance recommends the four-agent combination of statin + ezetimibe + PCSK9i + bempedoic acid [92]. Non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, bile acid sequestrants, fibrates, EPA/icosapent ethyl, nicotinic acid, and/or coenzyme Q10 are also recommended for patients with statin intolerance [28,[30], [31], [32],37,40,[42], [43], [44], [45], [46], [47], [48], [49],51,53,54,58,63,[65], [66], [67],73,80,83,88,92,93,95]. Summaries of common lipid management recommendations for patients in the general population who are at risk of or diagnosed with ASCVD are provided in Table 1. Table 1Summary of common lipid management recommendations for patients at risk of or diagnosed with ASCVD.Table 1Patient groupLipid management recommendationsAt risk of ASCVDLipid testing•Lipid profile once every 5 years to annually [[28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59]]LDL-C goals•Moderate/intermediate risk: <100 mg/dL [[28], [29], [30],32,33,36,39,40,42,46,47,52,60]•High CV risk: <100 mg/dL [34,35,38,40,42,43,45,54,55,59,62,65] or <70 mg/dL [[28], [29], [30],32,33,36,47,49,[51], [52], [53],58,60,66]•Very high CV risk: <70 mg/dL [30,40,42,59,62,68] or <50-55 mg/dL [28,29,32,36,47,[51], [52], [53],58,60,66]Lifestyle modifications•Healthy diet, regular physical activity, weight management, and smoking cessation [28,[30], [31], [32], [33], [34], [35], [36], [37],[39], [40], [41], [42], [43], [44], [45], [46], [47],51,[53], [54], [55], [56], [57], [58], [59],[61], [62], [63], [64], [65],67,69]Lipid-lowering treatment•Initial LLT: statin [28,[30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47],49,[51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65],[67], [68], [69], [70], [71]]•If not meeting initial LLT goals: statin + ezetimibe, bile acid sequestrant, bempedoic acid, and/or PCSK9i [28,[30], [31], [32], [33],[35], [36], [37],[39], [40], [41], [42], [43],45,47,[51], [52], [53], [54], [55], [56],[58], [59], [60],62,65,67]•If not meeting second-line LLT goals: statin + ezetimibe + PCSK9i [28,32,35,37,39,40,43,47,51,56,58,60,72]•If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [28,[30], [31], [32],[34], [35], [36], [37],39,40,42,43,[45], [46], [47],51,[53], [54], [55], [56],58,59,63,65,67,70]Diagnosed with ASCVDLipid testing•Lipid profile, as soon as possible in patients with ACS [30,43,48,59,[74], [75], [76], [77], [78], [79], [80]]LDL-C goals•ASCVD (with or without other major risk factors) or one severe ASCVD event: <70 mg/dL [33,34,38,40,42,43,48,49,54,59,62,65,68,74,[81], [82], [83], [84], [85], [86], [87], [88], [89], [90]] or <50-55 mg/dL [[28], [29], [30],32,42,46,47,51,52,58,60,63,66,70,78,80,83,[91], [92], [93], [94], [95], [96]]•Two severe ASCVD events or one severe event with ≥2 major risk factors: <40 mg/dL [28,29,32,47,51,80,92]Lifestyle modifications•Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[28], [29], [30], [31], [32],34,37,[40], [41], [42], [43],[45], [46], [47], [48],50,51,53,54,[56], [57], [58], [59],[63], [64], [65], [66], [67],69,[74], [75], [76],80,[83], [84], [85],87,90,[94], [95], [96],98]Lipid-lowering treatment•Initial LLT: statin or statin + ezetimibe [28,30,31,34,37,[40], [41], [42], [43],[45], [46], [47], [48], [49], [50], [51], [52], [53], [54],[56], [57], [58], [59], [60],63,64,66,67,69,70,72,74,75,[77], [78], [79], [80], [81], [82], [83],[85], [86], [87], [88], [89], [90], [91],[93], [94], [95], [96], [97], [98]]•If not meeting LLT goals: statin + ezetimibe, PCSK9i, bile acid sequestrant, and/or bempedoic acid [[28], [29], [30], [31], [32],34,37,40,[42], [43], [44], [45], [46], [47], [48], [49],[51], [52], [53], [54],[56], [57], [58],60,63,[65], [66], [67],70,72,74,78,80,81,84,85,88,[90], [91], [92], [93], [94], [95],97,98]•If not meeting second-line LLT goals: statin + ezetimibe + PCSK9i [28,31,37,43,[46], [47], [48],51,54,56,58,60,66,70,72,73,78,90,91,[93], [94], [95],100]•If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, bile acid sequestrants, fibrates, EPA/icosapent ethyl, nicotinic acid, and/or coenzyme Q10 [28,30-32,37,40,42-49,51,53,54,58,63,65-67,73,80,83,88,92,93,95] Summary of common lipid management recommendations for patients at risk of or diagnosed with ASCVD. •Lipid profile once every 5 years to annually [[28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59]] Lipid profile once every 5 years to annually [[28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59]] •Moderate/intermediate risk: <100 mg/dL [[28], [29], [30],32,33,36,39,40,42,46,47,52,60] Moderate/intermediate risk: <100 mg/dL [[28], [29], [30],32,33,36,39,40,42,46,47,52,60] •High CV risk: <100 mg/dL [34,35,38,40,42,43,45,54,55,59,62,65] or <70 mg/dL [[28], [29], [30],32,33,36,47,49,[51], [52], [53],58,60,66] High CV risk: <100 mg/dL [34,35,38,40,42,43,45,54,55,59,62,65] or <70 mg/dL [[28], [29], [30],32,33,36,47,49,[51], [52], [53],58,60,66] •Very high CV risk: <70 mg/dL [30,40,42,59,62,68] or <50-55 mg/dL [28,29,32,36,47,[51], [52], [53],58,60,66] Very high CV risk: <70 mg/dL [30,40,42,59,62,68] or <50-55 mg/dL [28,29,32,36,47,[51], [52], [53],58,60,66] •Healthy diet, regular physical activity, weight management, and smoking cessation [28,[30], [31], [32], [33], [34], [35], [36], [37],[39], [40], [41], [42], [43], [44], [45], [46], [47],51,[53], [54], [55], [56], [57], [58], [59],[61], [62], [63], [64], [65],67,69] Healthy diet, regular physical activity, weight management, and smoking cessation [28,[30], [31], [32], [33], [34], [35], [36], [37],[39], [40], [41], [42], [43], [44], [45], [46], [47],51,[53], [54], [55], [56], [57], [58], [59],[61], [62], [63], [64], [65],67,69] •Initial LLT: statin [28,[30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47],49,[51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65],[67], [68], [69], [70], [71]] Initial LLT: statin [28,[30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47],49,[51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65],[67], [68], [69], [70], [71]] •If not meeting initial LLT goals: statin + ezetimibe, bile acid sequestrant, bempedoic acid, and/or PCSK9i [28,[30], [31], [32], [33],[35], [36], [37],[39], [40], [41], [42], [43],45,47,[51], [52], [53], [54], [55], [56],[58], [59], [60],62,65,67] If not meeting initial LLT goals: statin + ezetimibe, bile acid sequestrant, bempedoic acid, and/or PCSK9i [28,[30], [31], [32], [33],[35], [36], [37],[39], [40], [41], [42], [43],45,47,[51], [52], [53], [54], [55], [56],[58], [59], [60],62,65,67] •If not meeting second-line LLT goals: statin + ezetimibe + PCSK9i [28,32,35,37,39,40,43,47,51,56,58,60,72] If not meeting second-line LLT goals: statin + ezetimibe + PCSK9i [28,32,35,37,39,40,43,47,51,56,58,60,72] •If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [28,[30], [31], [32],[34], [35], [36], [37],39,40,42,43,[45], [46], [47],51,[53], [54], [55], [56],58,59,63,65,67,70] If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [28,[30], [31], [32],[34], [35], [36], [37],39,40,42,43,[45], [46], [47],51,[53], [54], [55], [56],58,59,63,65,67,70] •Lipid profile, as soon as possible in patients with ACS [30,43,48,59,[74], [75], [76], [77], [78], [79], [80]] Lipid profile, as soon as possible in patients with ACS [30,43,48,59,[74], [75], [76], [77], [78], [79], [80]] •ASCVD (with or without other major risk factors) or one severe ASCVD event: <70 mg/dL [33,34,38,40,42,43,48,49,54,59,62,65,68,74,[81], [82], [83], [84], [85], [86], [87], [88], [89], [90]] or <50-55 mg/dL [[28], [29], [30],32,42,46,47,51,52,58,60,63,66,70,78,80,83,[91], [92], [93], [94], [95], [96]] ASCVD (with or without other major risk factors) or one severe ASCVD event: <70 mg/dL [33,34,38,40,42,43,48,49,54,59,62,65,68,74,[81], [82], [83], [84], [85], [86], [87], [88], [89], [90]] or <50-55 mg/dL [[28], [29], [30],32,42,46,47,51,52,58,60,63,66,70,78,80,83,[91], [92], [93], [94], [95], [96]] •Two severe ASCVD events or one severe event with ≥2 major risk factors: <40 mg/dL [28,29,32,47,51,80,92] Two severe ASCVD events or one severe event with ≥2 major risk factors: <40 mg/dL [28,29,32,47,51,80,92] •Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[28], [29], [30], [31], [32],34,37,[40], [41], [42], [43],[45], [46], [47], [48],50,51,53,54,[56], [57], [58], [59],[63], [64], [65], [66], [67],69,[74], [75], [76],80,[83], [84], [85],87,90,[94], [95], [96],98] Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[28], [29], [30], [31], [32],34,37,[40], [41], [42], [43],[45], [46], [47], [48],50,51,53,54,[56], [57], [58], [59],[63], [64], [65], [66], [67],69,[74], [75], [76],80,[83], [84], [85],87,90,[94], [95], [96],98] •Initial LLT: statin or statin + ezetimibe [28,30,31,34,37,[40], [41], [42], [43],[45], [46], [47], [48], [49], [50], [51], [52], [53], [54],[56], [57], [58], [59], [60],63,64,66,67,69,70,72,74,75,[77], [78], [79], [80], [81], [82], [83],[85], [86], [87], [88], [89], [90], [91],[93], [94], [95], [96], [97], [98]] Initial LLT: statin or statin + ezetimibe [28,30,31,34,37,[40], [41], [42], [43],[45], [46], [47], [48], [49], [50], [51], [52], [53], [54],[56], [57], [58], [59], [60],63,64,66,67,69,70,72,74,75,[77], [78], [79], [80], [81], [82], [83],[85], [86], [87], [88], [89], [90], [91],[93], [94], [95], [96], [97], [98]] •If not meeting LLT goals: statin + ezetimibe, PCSK9i, bile acid sequestrant, and/or bempedoic acid [[28], [29], [30], [31], [32],34,37,40,[42], [43], [44], [45], [46], [47], [48], [49],[51], [52], [53], [54],[56], [57], [58],60,63,[65], [66], [67],70,72,74,78,80,81,84,85,88,[90], [91], [92], [93], [94], [95],97,98] If not meeting LLT goals: statin + ezetimibe, PCSK9i, bile acid sequestrant, and/or bempedoic acid [[28], [29], [30], [31], [32],34,37,40,[42], [43], [44], [45], [46], [47], [48], [49],[51], [52], [53], [54],[56], [57], [58],60,63,[65], [66], [67],70,72,74,78,80,81,84,85,88,[90], [91], [92], [93], [94], [95],97,98] •If not meeting second-line LLT goals: statin + ezetimibe + PCSK9i [28,31,37,43,[46], [47], [48],51,54,56,58,60,66,70,72,73,78,90,91,[93], [94], [95],100] If not meeting second-line LLT goals: statin + ezetimibe + PCSK9i [28,31,37,43,[46], [47], [48],51,54,56,58,60,66,70,72,73,78,90,91,[93], [94], [95],100] •If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, bile acid sequestrants, fibrates, EPA/icosapent ethyl, nicotinic acid, and/or coenzyme Q10 [28,30-32,37,40,42-49,51,53,54,58,63,65-67,73,80,83,88,92,93,95] If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, bile acid sequestrants, fibrates, EPA/icosapent ethyl, nicotinic acid, and/or coenzyme Q10 [28,30-32,37,40,42-49,51,53,54,58,63,65-67,73,80,83,88,92,93,95] Specific comorbidity subgroups Diabetes mellitus Lipid testing and CV risk assessment. Clinical guidance specific to patients with DM advises a lipid profile upon DM diagnosis and at least annually thereafter [42,48,54,71,83,[101], [102], [103], [104], [105], [106]]. LDL-C goals. Clinical guidance typically recommends an LDL-C goal of <100 mg/dL for DM patients with moderate CV risk (e.g., T2DM lasting <10 years or T1DM lasting <20 years, 0 or 1 additional risk factor, no target organ damage) [45,46,54,63,65,66,68,71,83,[101], [102], [103],105,[107], [108], [109], [110]], <70 mg/dL (or 50% reduction from baseline without mention of specific target levels [37,61,104]) for DM patients with high CV risk (e.g., T2DM lasting >10 years, T1DM lasting >20 years, subclinical or no ASCVD, non-severe target organ damage, ≥1 additional risk factor, men aged >49 years or women aged >56 years) [28,34,39,[45], [46], [47],54,58,59,63,66,[101], [102], [103],[105], [106], [107], [108], [109],[111], [112], [113], [114]], and <55 mg/dL for DM patients with very or extremely high CV risk (e.g., diagnosed with ASCVD, previous ACS, severe target organ damage, or ≥3 risk factors) [47,58,63,66,83,[101], [102], [103],105,107,108,111,113,114]. However, Thai guidance recommends an LDL-C goal of <100 or <70 mg/dL for T2DM patients with ≥2 additional risk factors aged <40 or >40 years, respectively [46]; Japanese guidance documents recommend an LDL-C goal of <100 mg/dL for patients with DM complicated by PAD, microangiopathy, or the presence of smoking [64] or an LDL-C goal of <100 or <120 mg/dL for DM patients with or without a history of CAD, respectively [112]; and Malaysian guidance recommends that DM patients achieve the same risk-dependent goals as individuals without DM [59]. Lifestyle modifications. Clinical guidance commonly recommends that patients with DM adopt a healthy diet, regularly engage in physical activity, manage their weight, cease smoking, and moderate their alcohol consumption [[29], [30], [31],37,[46], [47], [48],54,58,59,63,66,69,108]. Lipid-lowering treatment. Statin alone is typically recommended as initial pharmacological LLT for DM patients at risk of or diagnosed with ASCVD [[28], [29], [30], [31], [32],37,[45], [46], [47], [48],50,51,54,58,59,61,63,65,66,69,71,[101], [102], [103], [104], [105], [106], [107], [108], [109],[111], [112], [113], [114], [115]]. Many guidance documents also recommend statin + ezetimibe as another initial LLT option for certain DM patients, such as those who are diagnosed with ASCVD or have marked elevations in LDL-C, target organ damage or ≥3 major risk factors, T1DM with early onset and long duration, or concomitant CKD [29,30,92,104,107]. Some guidance documents also recommend statin + PCSK9i or fibrate [[111], [112], [113]]. For DM patients not meeting initial LLT goals, guidance typically recommends adding ezetimibe [28,32,37,[45], [46], [47],58,66,101,103,105,108,116], PCSK9i [30,106], or ezetimibe or PCSK9i [29,65,102,104,107,111,113]. However, Iranian guidance recommends ezetimibe or a bile acid sequestrant [31], international guidance recommends ezetimibe + bempedoic acid [92], Malaysian guidance recommends a fibrate [59], and UK guidance recommends any other LLT (e.g., ezetimibe, PCSK9i) [48]. For DM patients not meeting goals on second-line LLT and requiring third-line LLT, guidance recommends the addition of a PCSK9i [105], ezetimibe + PCSK9i [28,31,46,66,101] (or ezetimibe + bile acid sequestrant if the patient is unable to use PCSK9i [46]), ezetimibe + bempedoic acid [48], ezetimibe + bempedoic acid + PCSK9i [92], or PCSK9i, bempedoic acid, or a fibrate [103]. Non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants are also recommended for DM patients with statin intolerance [28,[30], [31], [32],37,45,46,48,63,66,92,101,103,106,107,111,116]. Chronic kidney disease Lipid testing. Clinical guidance specific to patients with CKD advises a lipid profile upon CKD diagnosis [54,89]. For kidney transplant recipients, a lipid profile is recommended 2-3 months after transplantation and at least annually thereafter [117,118]. LDL-C goals. European [58] and Thai [46] guidance documents recommend an LDL-C goal of <100 mg/dL for CKD patients, whereas Indian guidance recommends a goal of LDL-C <70 mg/dL [53]. European guidance further recommends that high- or very high-risk CKD patients achieve more aggressive goals of LDL-C <70 or <55 mg/dL, respectively [58]. Finally, Greek guidance recommends different LDL-C goals depending on disease stage (i.e., stage 3: <70 mg/dL, stage 4-5: <55 mg/dL) [66], and Malaysian guidance recommends that CKD patients achieve the same risk-dependent goals as individuals without CKD [59]. Kidney transplant recipients are advised to achieve an LDL-C goal of <100 mg/dL [117] or the same as that for individuals in the general population [118]. Lifestyle modifications. Clinical guidance commonly recommends that patients with CKD adopt a healthy diet, regularly engage in physical activity, manage their weight, cease smoking, and moderate their alcohol consumption [[29], [30], [31], [32],34,37,39,43,[46], [47], [48],53,54,56,58,59,63,64,66,69,83,117]. Lipid-lowering treatment. Statin alone or statin + ezetimibe are recommended as initial pharmacological LLT for CKD patients at risk of or diagnosed with ASCVD [[29], [30], [31], [32],37,39,43,[46], [47], [48],53,54,56,58,59,63,64,66,69,83]. For CKD patients not meeting LLT goals as determined by their healthcare providers, US guidance recommends the addition of ezetimibe [37], and Polish [32] and Saudi Arabian [29] guidance documents recommend the addition of ezetimibe + PCSK9i. Ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants are recommended for CKD patients with statin intolerance [31,32,37,46,48,63,66]. Guidance documents from around the world state that commencement of LLT is not recommended for end-stage CKD patients on dialysis [30,32,34,37,39,43,46,47,54,58,59,66,83,102], although some guidance documents note that LLT commenced before dialysis can be continued during dialysis [32,34,37,43,46,47,102]. A statin is recommended as initial pharmacological LLT for kidney transplant recipients [46,54,66,117,118]. European guidance recommends the addition of ezetimibe or a fibrate for kidney transplant recipients not meeting LLT goals [117], and guidance documents from Greece [66] and the Philippines [46] recommend ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants for those with statin intolerance. For CKD patients with DM, statins are recommended as initial pharmacological LLT [107,113], with statin + ezetimibe recommended as another initial LLT option for CKD patients with T2DM [107] or as a second-line option for CKD patients with T1DM not meeting LLT goals [113]. Obesity Lipid testing. Clinical guidance specific to patients with obesity advises a lipid profile [113,119], with retesting after 5% weight loss and periodically thereafter once weight is stable [113]. LDL-C goals. No guidance documents make recommendations for LDL-C goals specifically for patients with obesity. Lifestyle modifications. Clinical guidance commonly recommends that patients with obesity adopt a healthy diet, regularly engage in physical activity, reduce their stress, and practice healthy sleep habits [113,119,120]. Lipid-lowering treatment. Statin alone is recommended as initial pharmacological LLT by US guidance for patients with obesity and high CV risk due to metabolic syndrome, prediabetes, or hypertension [119] and by European guidance for patients with both obesity and T1DM irrespective of CV risk classification [113] or patients on a continuum of obesity leading to metabolic syndrome leading to DM culminating in heart failure with preserved ejection fraction [120]. For patients not meeting LLT goals as determined by their healthcare providers, European guidance recommends the addition of ezetimibe [120]. Summaries of common lipid management recommendations for patients with DM, CKD, or obesity are provided in Table 2. Table 2Summary of common lipid management recommendations for patients with DM, CKD, or obesity.Table 2Patient groupLipid management recommendationsDMLipid testing•Lipid profile upon DM diagnosis and at least annually thereafter [42,48,54,71,83,[101], [102], [103], [104], [105], [106]]LDL-C goals•Moderate CV risk: <100 mg/dL [45,46,54,63,65,66,68,71,83,[101], [102], [103],105,[107], [108], [109], [110]]•High CV risk: <70 mg/dL [28,34,39,[45], [46], [47],54,58,59,63,66,[101], [102], [103],[105], [106], [107], [108], [109],[111], [112], [113], [114]]•Very/extremely high CV risk: <55 mg/dL [47,58,63,66,83,[101], [102], [103],105,107,108,111,113,114]Lifestyle modifications•Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[29], [30], [31],37,[46], [47], [48],54,58,59,63,66,69,108]Lipid-lowering treatment•Initial LLT: statin [[28], [29], [30], [31], [32],37,[45], [46], [47], [48],50,51,54,58,59,61,63,65,66,69,71,[101], [102], [103], [104], [105], [106], [107], [108], [109],[111], [112], [113], [114], [115]]•If not meeting initial LLT goals: statin + ezetimibe or PCSK9i [[28], [29], [30], [31], [32],37,[45], [46], [47], [48],58,59,65,66,92,[101], [102], [103], [104], [105], [106], [107], [108],111,113,116]•If not meeting second-line LLT goals: statin + ezetimibe, PCSK9i, and/or bempedoic acid [28,31,46,48,66,92,101,103,105]•If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [28,[30], [31], [32],37,45,46,48,63,66,92,101,103,106,107,111,116]CKDLipid testing•Lipid profile upon CKD diagnosis [54,89]LDL-C goals•<100, <70, or <55 mg/dL depending on disease stage or CV risk [58,59,66]Lifestyle modifications•Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[29], [30], [31], [32],34,37,39,43,[46], [47], [48],53,54,56,58,59,63,64,66,69,83,117]Lipid-lowering treatment•Initial LLT: statin or statin + ezetimibe [[29], [30], [31], [32],37,39,43,[46], [47], [48],53,54,56,58,59,63,64,66,69,83]•If not meeting LLT goals: statin + ezetimibe and/or PCSK9i [32,37]•If statin intolerant: ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [31,32,37,46,48,63,66]•If on dialysis: commencement of LLT not recommended [30,32,34,37,39,43,46,47,54,58,59,66,83]•If received kidney transplantation: similar recommendations as for CKD patients not on dialysis [46,54,66,117,118]ObesityLipid testing•Lipid profile [119]LDL-C goals•No specific recommendationsLifestyle modifications•Healthy diet, regular physical activity, stress management, healthy sleep habits [113,119,120]Lipid-lowering treatment•Initial LLT: statin [113,119,120]•If not meeting initial LLT goals: statin + ezetimibe [120] Summary of common lipid management recommendations for patients with DM, CKD, or obesity. •Lipid profile upon DM diagnosis and at least annually thereafter [42,48,54,71,83,[101], [102], [103], [104], [105], [106]] Lipid profile upon DM diagnosis and at least annually thereafter [42,48,54,71,83,[101], [102], [103], [104], [105], [106]] •Moderate CV risk: <100 mg/dL [45,46,54,63,65,66,68,71,83,[101], [102], [103],105,[107], [108], [109], [110]] Moderate CV risk: <100 mg/dL [45,46,54,63,65,66,68,71,83,[101], [102], [103],105,[107], [108], [109], [110]] •High CV risk: <70 mg/dL [28,34,39,[45], [46], [47],54,58,59,63,66,[101], [102], [103],[105], [106], [107], [108], [109],[111], [112], [113], [114]] High CV risk: <70 mg/dL [28,34,39,[45], [46], [47],54,58,59,63,66,[101], [102], [103],[105], [106], [107], [108], [109],[111], [112], [113], [114]] •Very/extremely high CV risk: <55 mg/dL [47,58,63,66,83,[101], [102], [103],105,107,108,111,113,114] Very/extremely high CV risk: <55 mg/dL [47,58,63,66,83,[101], [102], [103],105,107,108,111,113,114] •Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[29], [30], [31],37,[46], [47], [48],54,58,59,63,66,69,108] Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[29], [30], [31],37,[46], [47], [48],54,58,59,63,66,69,108] •Initial LLT: statin [[28], [29], [30], [31], [32],37,[45], [46], [47], [48],50,51,54,58,59,61,63,65,66,69,71,[101], [102], [103], [104], [105], [106], [107], [108], [109],[111], [112], [113], [114], [115]] Initial LLT: statin [[28], [29], [30], [31], [32],37,[45], [46], [47], [48],50,51,54,58,59,61,63,65,66,69,71,[101], [102], [103], [104], [105], [106], [107], [108], [109],[111], [112], [113], [114], [115]] •If not meeting initial LLT goals: statin + ezetimibe or PCSK9i [[28], [29], [30], [31], [32],37,[45], [46], [47], [48],58,59,65,66,92,[101], [102], [103], [104], [105], [106], [107], [108],111,113,116] If not meeting initial LLT goals: statin + ezetimibe or PCSK9i [[28], [29], [30], [31], [32],37,[45], [46], [47], [48],58,59,65,66,92,[101], [102], [103], [104], [105], [106], [107], [108],111,113,116] •If not meeting second-line LLT goals: statin + ezetimibe, PCSK9i, and/or bempedoic acid [28,31,46,48,66,92,101,103,105] If not meeting second-line LLT goals: statin + ezetimibe, PCSK9i, and/or bempedoic acid [28,31,46,48,66,92,101,103,105] •If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [28,[30], [31], [32],37,45,46,48,63,66,92,101,103,106,107,111,116] If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [28,[30], [31], [32],37,45,46,48,63,66,92,101,103,106,107,111,116] •Lipid profile upon CKD diagnosis [54,89] Lipid profile upon CKD diagnosis [54,89] •<100, <70, or <55 mg/dL depending on disease stage or CV risk [58,59,66] <100, <70, or <55 mg/dL depending on disease stage or CV risk [58,59,66] •Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[29], [30], [31], [32],34,37,39,43,[46], [47], [48],53,54,56,58,59,63,64,66,69,83,117] Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[29], [30], [31], [32],34,37,39,43,[46], [47], [48],53,54,56,58,59,63,64,66,69,83,117] •Initial LLT: statin or statin + ezetimibe [[29], [30], [31], [32],37,39,43,[46], [47], [48],53,54,56,58,59,63,64,66,69,83] Initial LLT: statin or statin + ezetimibe [[29], [30], [31], [32],37,39,43,[46], [47], [48],53,54,56,58,59,63,64,66,69,83] •If not meeting LLT goals: statin + ezetimibe and/or PCSK9i [32,37] If not meeting LLT goals: statin + ezetimibe and/or PCSK9i [32,37] •If statin intolerant: ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [31,32,37,46,48,63,66] If statin intolerant: ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [31,32,37,46,48,63,66] •If on dialysis: commencement of LLT not recommended [30,32,34,37,39,43,46,47,54,58,59,66,83] If on dialysis: commencement of LLT not recommended [30,32,34,37,39,43,46,47,54,58,59,66,83] •If received kidney transplantation: similar recommendations as for CKD patients not on dialysis [46,54,66,117,118] If received kidney transplantation: similar recommendations as for CKD patients not on dialysis [46,54,66,117,118] •Lipid profile [119] Lipid profile [119] •No specific recommendations No specific recommendations •Healthy diet, regular physical activity, stress management, healthy sleep habits [113,119,120] Healthy diet, regular physical activity, stress management, healthy sleep habits [113,119,120] •Initial LLT: statin [113,119,120] Initial LLT: statin [113,119,120] •If not meeting initial LLT goals: statin + ezetimibe [120] If not meeting initial LLT goals: statin + ezetimibe [120] Specific demographic subgroups Older adults Lipid testing. European and US guidance documents recommend that older adults (i.e., aged ≥65 years or referred to as “older” or “elderly”) who are apparently healthy or with minimal risk factors undergo a lipid profile every 5 years [58,100] or annually [42], whereas Canadian guidance recommends that older adults do not undergo routine lipid testing for primary prevention [44]. LDL-C goals. Greek clinical guidance recommends that moderate-, high-, or very high-risk older adults achieve an LDL-C goal of <100, <70, or <55 mg/dL, respectively [66], and French guidance recommends that older adults in the secondary prevention setting achieve an LDL-C goal of <100 mg/dL [34]. Lifestyle modifications. Clinical guidance commonly recommends that older adults adopt a healthy diet, regularly engage in physical activity, manage their weight, cease smoking, and moderate their alcohol consumption [31,34,37,43,47,58,59,64,66]. Lipid-lowering treatment. Statin alone is typically recommended as first-line LLT for older adults at risk of or diagnosed with ASCVD [31,34,37,43,47,[58], [59], [60],64,66,91,100,115], with many advising low or moderate starting doses, particularly in situations of renal impairment or potential drug interactions. However, some guidance documents recommend using a statin only for certain older adults, such as those without severe comorbidities, at the physician's discretion or after discussion with the patient about potential benefits and side effects [44,55,65,111]. Whereas Iranian guidance recommends stopping statins in older adults in the presence of multiple diseases, reduced physical or cognitive function, or decreased life expectancy [31], Canadian guidance recommends against stopping statins or reducing the dose in patients aged ≥75 years or who begin to exhibit cognitive concerns [44]. For older adults not meeting LLT goals as determined by their healthcare providers, European guidance recommends the addition of ezetimibe or a bile acid sequestrant [58], Chinese guidance recommends ezetimibe or PCSK9i [65], and US guidance recommends ezetimibe [100]. Non-statin LLTs such as ezetimibe, PCSK9i, bile acid sequestrants, niacin, and/or bempedoic acid are also recommended for older adults with statin intolerance [58,66,100,111]. Women Lipid testing. Clinical guidance recommends a lipid profile for women aged <45 years who experience early menopause [113] or for women aged >40 years [59]. A lipid profile is also recommended for women who are planning pregnancy [100] or during the late postpartum period in women with a history of pregnancy complications [50], but routine lipid testing is not recommended during pregnancy due to unreliability in the interpretation of lipid levels resulting from normal pregnancy-induced physiologic changes [121,122]. LDL-C goals. Malaysian guidance recommends that women achieve an LDL-C <115 mg/dL if they have one major CV risk factor, <100 mg/dL if they are high-risk (e.g., diagnosed with ASCVD, abdominal aortic aneurysm, DM, CKD, multiple CV risk factors), and <70 mg/dL if they have both ASCVD and DM [110]. Lifestyle modifications. Clinical guidance commonly recommends that women adopt a healthy diet, regularly engage in physical activity, manage their weight, cease smoking, and moderate their alcohol consumption [[29], [30], [31], [32],37,47,48,58,64,66,110]. Lipid-lowering treatment. European [66,113] and Malaysian [110] guidance documents recommend a statin as initial pharmacological LLT in primary or secondary prevention settings, whereas Japanese [64] guidance recommends considering a statin only in women who have FH, other high-risk factors, or are in secondary prevention settings. Most guidance documents do not recommend commencing or continuing LLT in women who are planning pregnancy, pregnant, or breastfeeding [29,32,37,47,48,54,56,58,59,64,66,102,104,106,110,121]. However, some guidance documents state that LLT, particularly bile acid sequestrants, may be considered in high- or very high-risk pregnant women, such as those with FH, highly elevated LDL-C, ASCVD, or previous ACS [30,31,45,47,65,100]. European guidance recommends ezetimibe, PCSK9 inhibitors, bempedoic acid, and/or bile acid sequestrants for women with statin intolerance [66]. Summaries of common lipid management recommendations for older adults and women are provided in Table 3. Table 3Summary of common lipid management recommendations for older adults or women.Table 3Patient groupLipid management recommendationsOlder adultsLipid testing•Lipid profile every 5 years or annually [42,44,58,100]LDL-C goals•<100, <70, or <55 mg/dL depending on CV risk or history of ASCVD [34,66]Lifestyle modifications•Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [31,34,37,43,47,58,59,64,66]Lipid-lowering treatment•Initial LLT: statin, preferably at low or moderate dose [31,34,37,43,47,[58], [59], [60],64,66,91,100,115]•If not meeting initial LLT goals: statin + ezetimibe, bile acid sequestrant, or PCSK9i [58,65,100]•If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bile acid sequestrants, niacin, and/or bempedoic acid [58,66,100,111]WomenLipid testing•Lipid profile for certain women [50,59,100,113]LDL-C goals•<115, <100, <70 mg/dL depending on CV risk [110]Lifestyle modifications•Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[29], [30], [31], [32],37,47,48,58,64,66,110]Lipid-lowering treatment•Initial LLT: statin [66,110,113]•If statin intolerant: ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [66] Summary of common lipid management recommendations for older adults or women. •Lipid profile every 5 years or annually [42,44,58,100] Lipid profile every 5 years or annually [42,44,58,100] •<100, <70, or <55 mg/dL depending on CV risk or history of ASCVD [34,66] <100, <70, or <55 mg/dL depending on CV risk or history of ASCVD [34,66] •Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [31,34,37,43,47,58,59,64,66] Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [31,34,37,43,47,58,59,64,66] •Initial LLT: statin, preferably at low or moderate dose [31,34,37,43,47,[58], [59], [60],64,66,91,100,115] Initial LLT: statin, preferably at low or moderate dose [31,34,37,43,47,[58], [59], [60],64,66,91,100,115] •If not meeting initial LLT goals: statin + ezetimibe, bile acid sequestrant, or PCSK9i [58,65,100] If not meeting initial LLT goals: statin + ezetimibe, bile acid sequestrant, or PCSK9i [58,65,100] •If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bile acid sequestrants, niacin, and/or bempedoic acid [58,66,100,111] If statin intolerant: non-statin LLTs such as ezetimibe, PCSK9i, bile acid sequestrants, niacin, and/or bempedoic acid [58,66,100,111] •Lipid profile for certain women [50,59,100,113] Lipid profile for certain women [50,59,100,113] •<115, <100, <70 mg/dL depending on CV risk [110] <115, <100, <70 mg/dL depending on CV risk [110] •Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[29], [30], [31], [32],37,47,48,58,64,66,110] Healthy diet, regular physical activity, weight management, smoking cessation, and moderation of alcohol consumption [[29], [30], [31], [32],37,47,48,58,64,66,110] •Initial LLT: statin [66,110,113] Initial LLT: statin [66,110,113] •If statin intolerant: ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [66] If statin intolerant: ezetimibe, PCSK9i, bempedoic acid, and/or bile acid sequestrants [66] Discussion This global systematic review of 109 clinical practice guidelines and expert consensus statements on lipid management reveals both convergence and divergence in recommendations for adults at risk of or diagnosed with ASCVD. While many clinical guidance documents share foundational principles, such as the importance of LDL-C testing and lifestyle modifications and the use of statins as initial LLT, they exhibit substantial variation in other recommendations. For example, European [47,58,60,66,80,91,94,95] guidance often recommends an LDL-C goal of <55 mg/dL for patients with established ASCVD, whereas Asian-Pacific [46,53,54,59,62,64,65,83,84,89,90,97,99] and North American [45,74,85,86] guidance documents more commonly recommend an LDL-C goal of <70 mg/dL. Although such variation may reflect deliberate contextualization to differences in population risk profiles, ethnic and cultural factors, healthcare system capacity, and access to LLTs across regions, different recommendations are also observed among guidance documents originating from the same country. For instance, earlier Canadian guidance recommends delivering LLT to meet specific lipid targets [41], whereas later Canadian guidance recommends against targeting specific lipid levels after starting LLT [44]. Also, while guidance often recommends non-statin LLTs such as ezetimibe and PCSK9i for patients who do not meet LDL-C goals on statins, the recommended sequencing and combination of these agents vary widely. Furthermore, patient subgroup-specific recommendations are unevenly distributed. Patients with DM and CKD are frequently addressed in clinical guidance, with relatively consistent recommendations on LLT and treatment goals. By contrast, recommendations for patients with obesity, older adults, and women are sparse and often lack LDL-C targets or tailored LLT strategies. The variation in LDL-C goals observed across clinical guidance is particularly noteworthy because lower LDL-C targets are supported by a substantial body of evidence demonstrating a relationship between LDL-C reduction and improved CV outcomes. Large meta-analyses show that each 1 mmol/L (∼39 mg/dL) reduction in LDL-C is associated with a meaningful reduction in major vascular events, with benefits observed across a wide range of patient populations [[123], [124], [125], [126], [127]]. Furthermore, clinical trials evaluating intensive LDL-C lowering strategies, including IMPROVE-IT [128], FOURIER [129], ODYSSEY OUTCOMES [130], EZ-PAVE [131], and VESALIUS-CV [132,133], demonstrated that achieving lower LDL-C levels through the addition of ezetimibe or PCSK9i to statin therapy reduces the risk of recurrent CV events in high-risk patients. More recent analyses suggest a largely continuous relationship between achieved LDL-C level and CV risk, with event rates continuing to decline at LDL-C levels below traditional treatment thresholds and without major safety concerns [134]. These findings provide a biologic and clinical rationale for the increasingly stringent LDL-C goals adopted by several contemporary guidance documents, particularly for patients at very high CV risk. However, differences in interpretation of this evidence, uncertainty regarding the optimal threshold for treatment intensification, and consideration of cost-effectiveness and healthcare resource constraints may contribute to the persistence of different LDL-C goals across regions and organizations. Our findings align with other recent comparative reviews of clinical practice guidelines on lipid management in primary [12,135] or secondary [136] prevention settings, which note a lack of concordance in recommendations on LDL-C goals, the use of non-statin LLTs, and the intensification of therapy when patients’ lipid goals are not met. Such differences among guidance documents can arise due to multiple reasons, including differences in how guidance development panels are assembled and how these panels select and interpret research evidence and achieve consensus when formulating recommendations [8,137,138]. Furthermore, such differences in guidance development processes can be aggravated by economic disparities between geographical regions or countries, with one study showing a near-linear relationship between the rigor of guidance development and the gross domestic product per capita of the originating countries [139]. The existence of different recommendations for lipid management can create uncertainty for clinicians, particularly when managing patients with multiple comorbidities or those who fall outside traditional risk categories [140]. This ambiguity may contribute to clinical inertia, under-treatment, or inconsistent care [15]. Thus, to improve the consistency, clarity, and clinical uptake of lipid management guidance, several actions could be taken. First, collaborative efforts among professional societies could support alignment on foundational concepts—such as definitions of risk categories, evidentiary thresholds for initiating or intensifying therapy, and terminology—while preserving flexibility to account for population characteristics, healthcare system capacity, and access to therapies [141]. Second, guidance developers could use uniform processes for appraising the evidence and presenting recommendations, which would enhance transparency and improve comparability between guidance documents for patients with frequently comorbid conditions [137,142]. Third, to encourage the use of guidance by clinicians, user-friendly algorithms and decision aids could be developed that integrate recommendations from multiple guidance documents to reduce confusion and support individualized patient care [143,144]. Importantly, clinical guidance should support, rather than replace, individualized patient care. Although many recommendations are framed around population-level evidence, treatment decisions should consider each patient's overall CV risk, comorbidities, treatment preferences, likelihood of benefit, potential adverse effects, access to therapies, and economic considerations. Ultimately, the goal of lipid management is not only to achieve lipid targets but also to improve clinical outcomes in a manner that is appropriate for the individual patient's risk profile and treatment preferences [37,40]. In addition, increased investment in clinical trials and observational studies focused on women, older adults, and patients with obesity is essential for informing and strengthening recommendations for the care of these underrepresented populations [19,20,145,146]. Since the literature search was conducted in March 2025, clinical guidance published thereafter was not eligible for inclusion in the systematic review. Notably, the 2025 focused update of the 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias [147] and the 2026 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on the Management of Dyslipidemia [148] were released after completion of the evidence synthesis. Although these newer documents remain broadly aligned with many of the core principles identified in this review, they incorporate evolving evidence and, in some cases, modify recommendations regarding CV risk assessment, LDL-C targets, and the use of combination or non-statin LLT. For example, the updated ESC/EAS guideline further refines risk stratification among patients at the highest ASCVD risk and places greater emphasis on emerging risk enhancers such as lipoprotein(a), whereas the 2026 ACC/AHA guideline adopts more aggressive LDL-C treatment goals and a revised approach to CV risk assessment. Both guidelines continue to support risk-stratified approaches to lipid management while encouraging earlier treatment intensification and broader use of combination therapy to achieve LDL-C goals in higher-risk populations. Despite these updates, the overarching trends identified in this review remain unchanged, including increasing emphasis on individualized care, more intensive LDL-C lowering in higher-risk populations, recognition of emerging risk enhancers, and earlier use of combination and non-statin therapies. As evidence continues to evolve, including recent therapeutic advances and anticipated outcome data for emerging treatments, future guideline updates will likely continue this trend toward increasingly personalized and proactive lipid management. Strengths of this systematic review include its comprehensive literature search, use of two independent reviewers for guidance selection, and broad inclusion of both clinical practice guidelines and expert consensus statements from around the world covering diverse groups of patients at risk of or diagnosed with ASCVD. However, several limitations should also be acknowledged. First, the literature search was completed in March 2025 and thus did not capture subsequent major guideline updates, including the 2025 ESC/EAS focused update [147] and the 2026 ACC/AHA guideline [148]. Second, while this review highlights substantial variation across clinical guidance, such variation should not necessarily be interpreted as inappropriate or remediable through a single, unified global guideline. Differences in recommendations may appropriately reflect heterogeneity in population characteristics (e.g., ethnicity, age distribution, comorbidity burden), socioeconomic conditions, healthcare infrastructure, and access to LLTs across countries. In this context, divergence among guidelines may represent contextual adaptation rather than inconsistency in evidence interpretation. Third, only English-language guidance was eligible for inclusion. As a result, guidance developed and published exclusively in other languages may have been missed, particularly from regions such as Africa, Latin America, the Middle East, and parts of Asia. Consequently, the geographical distribution of included guidance should not be interpreted as a direct reflection of global guideline availability, and comparisons across regions may be influenced by differential representation rather than true differences in clinical recommendations. Fourth, some guidance documents contained vague or internally inconsistent recommendations, requiring reviewer judgement regarding the interpretation or authoritativeness of certain recommendations. In addition, several clinical guidelines were published early in the review period and may not fully reflect current evidence or newer therapeutic options. Finally, considerations related to cost, affordability, and reimbursement—which are central to national guideline development and implementation [149]—were not summarized due to their inconsistent reporting and region-specific nature. Conclusions In conclusion, this global systematic review shows that, despite broad agreement on core principles such as LDL-C assessment, lifestyle modifications, statin-based LLT, and treatment intensification for higher-risk patients, contemporary clinical guidance for lipid management in adults at risk of or diagnosed with ASCVD remains highly variable. Differences in recommended LDL-C goals, use and sequencing of non-statin LLTs, and the availability of subgroup-specific recommendations—particularly for individuals with obesity, older adults, and women—may contribute to clinical uncertainty and lead to inconsistent implementation and patient care. While some degree of variation may be expected given geographical differences in clinical and implementation contexts, the extent of divergence observed both across and within regions can complicate clinical decision-making, especially for providers managing patients with multiple comorbidities. These findings underscore the need for clearer, more methodologically consistent guidance and stronger evidence for underrepresented populations to support more consistent, equitable delivery of ASCVD prevention and treatment strategies. CRediT authorship contribution statement Katherine G. Akers: Writing – review & editing, Writing – original draft, Visualization, Validation, Project administration, Methodology, Investigation, Data curation, Conceptualization. Kara Nguyen: Writing – review & editing, Validation, Investigation. Andrew M. Frederickson: Writing – review & editing, Project administration, Methodology, Conceptualization. Lori D. Bash: Writing – review & editing, Supervision, Methodology, Conceptualization. Xuehua Ke: Writing – review & editing, Supervision, Project administration, Methodology, Conceptualization. Shaun G. Goodman: Writing – review & editing, Supervision, Methodology, Conceptualization. Data statement No new data were generated or analyzed in support of this research. Funding sources This study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Declaration of competing interests KG Akers, K Nguyen, and AM Frederickson are employees of Precision AQ, a healthcare research consulting firm that received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, to conduct the research described in this manuscript. LD Bash and X Ke are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. SD Goodman has received research grant support (e.g., steering committee) from Alnylam, Amgen, Anthos Therapeutics, Bayer, Boehringer Ingelheim, CSL Behring, CYTE Ltd., Esperion, Ferring Pharmaceuticals, Idorsia/Viatris, Novartis, Regeneron, Roche, and Sanofi; has performed consulting activities for Alnylam, Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck & Co., Inc., Rahway, NJ, USA, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Roche, Sanofi, Servier, Tolmar Pharmaceuticals, and Valeo Pharma; has given lectures, presentations, and educational events for Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, HLS Therapeutics, JAMP Pharma, Merck & Co., Inc., Rahway, NJ, USA, Novartis, Pendopharm/Pharmascience, Pfizer, Sanofi, Tolmar Pharmaceuticals, and Valeo Pharma; has served on data safety monitoring boards for Daiichi-Sankyo/American Regent, Eli Lilly, Novo Nordisk A/C, and Jewish General Hospital\CIUSSS Centre-Ouest-de-l'Ile-de-Montreal; has served on advisory boards for Alnylam, Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, HLS Therapeutics, Merck & Co., Inc., Rahway, NJ, USA, Novartis, Novo Nordisk A/C, and Sanofi; and has received salary support/honoraria from Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, Peter Munk Cardiac Centre Clinical Trials and Translation Unit, Ted Rogers Centre for Heart Research, and TIMI Study Group (Brigham Health). Acknowledgements We thank Asfar Khan (Precision AQ) for his contributions to study screening and data extraction. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.ijcrp.2026.200710. Contributor Information Katherine G. Akers, Email: katherine.akers@precisionaq.com. Kara Nguyen, Email: kara.nguyen@precisionaq.com. Andrew M. Frederickson, Email: andrew.frederickson@precisionaq.com. Lori D. Bash, Email: lori_bash@merck.com. Xuehua Ke, Email: xuehua.ke@merck.com. Shaun G. Goodman, Email: goodmans@chrc.net. Supplementary data The following is the Supplementary data to this article. Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1